Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/31/12
End: 12/21/16
Due: 12/21/17
Phase: N/A
Priority: Normal
Start: 06/30/14
End: 05/07/19
Due: 05/07/20
Phase: N/A
Priority: Normal
Start: 09/30/13
End: 05/31/16
Due: 05/31/17
Phase: N/A
Priority: Normal
Start: 03/26/18
End: 01/14/20
Due: 01/14/21
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) | NCT01651039 | Ajai Chari | user2@example.com | None | 2012-07-31 | 2016-12-21 | 2017-12-21 | - | - | 2025-07-14 |
| Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT02176213 | Ajai Chari | user2@example.com | None | 2014-06-30 | 2019-05-07 | 2020-05-07 | - | - | 2025-07-14 |
| Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib | NCT01775553 | Ajai Chari | user2@example.com | None | 2013-09-30 | 2016-05-31 | 2017-05-31 | - | - | 2025-07-14 |
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Ajai Chari | user2@example.com | None | 2018-03-26 | 2020-01-14 | 2021-01-14 | - | - | 2025-07-14 |